TCDB is operated by the Saier Lab Bioinformatics Group
« See all members of the family


2.A.57.2.3
High affinity, concentrative nucleoside (inosine, formycin, guanosine):H+ symporter, NT2 (Stein et al., 2003). Mutations confer drug (formycin) resistance and drug transport deficiency (Galazka et al. 2006). Asp389 is critical for transporter function without affecting ligand affinity or plasma membrane targeting, but Asn175 and Asp389 (when mutated as a second site mutation) lie in close proximity to each other; second-site suppressor mutations cluster to one region of the transporter, suggested that Asp175 is conformationally sensitive (Arastu-Kapur et al. 2005). Development of glutamatergic/cholinergic postmitotic human neurons is induced by short-term treatment with nucleoside analogues such as cytosine β-D-arabinofuranoside,  2'-O-methyl substituted 2-deoxy-β-D-ribofuranosyl residues as glyconic moieties, and cladribine (Raasch et al. 2015; González-Burguera et al. 2016).  

Accession Number:Q9NBV4
Protein Name:NT2
Length:499
Molecular Weight:54063.00
Species:Leishmania donovani [5661]
Number of TMSs:11
Location1 / Topology2 / Orientation3: Membrane1 / Multi-pass membrane protein2
Substrate Inosine, Formycin, Guanosine, H+

Cross database links:

Pfam: PF01733   

Gene Ontology

GO:0016020 C:membrane
GO:0005337 F:nucleoside transmembrane transporter activity
GO:0006810 P:transport

References (1)

[1] “Cloning of a novel inosine-guanosine transporter gene from Leishmania donovani by functional rescue of a transport-deficient mutant.”  Carter N.S.et.al.   10783393

External Searches:

Analyze:

Predict TMSs (Predict number of transmembrane segments)
Window Size: Angle:  
FASTA formatted sequence
1:	MTGQSAAVEG SNSALPWYRM GFHTLAEFNT YVTFVLLGMS IMMVTSAVTS APDFVTKYFI 
61:	YATGDPDAVA ETPLFWNNAN TFYNAGTYAM QVVTEIASLT PFMRSIPLGI RLFLGLGIPF 
121:	VELVVIIAVP AATIPTQNGA IAVIMVVAMM GGLSKALCDS CTNALVGPFP TKFMNGAQWG 
181:	LTVIALFMSI IQIILQVSMG STFQDVLTIS RIYFGIGIGI QVMAIAALVL LRYNPFAQKY 
241:	IAEFRAAALR RRGHVEPEES QDSKEPATGD VAEAPKAGEK EVTLDAMEEA DEVRAVPSDA 
301:	FVAKSGAVLQ ATGDADRMVD LDQTKNITST EQMLRASVWS VFKRIYPMLL CAFTIFFTTL 
361:	LVFPGVFFLV PARSGWYMTI IVTLFNAGDF VARVLLMIRV LRPSPKLVIV GTFGRLAVIP 
421:	LIVLCVRGFI PGVALPYVLI FLFGLTNGYF GTMSCIHCPR TPTLHYAGER SVAAMLAGIS 
481:	LMLGLCFGSN MSLAITLTY